Cabio Biotech (Wuhan) Co., Ltd.

688089.SS

688089.SSCabio Biotech (Wuhan) Co., Ltd. CN flag

Shanghai

21.30

CNY

-0.14

(-0.65%)

0.68EPS

31.32P/E

3.58BMarket Cap

Mar 21Next Earn

Upgrade to Unlock Non-US CompaniesTo view real-time data and analysis of companies outside of the United States, upgrade your account to our premium subscription.

Upgrade

ISIN

CNE100005X31

Return %

Stock

S&P500

16.39

31.12

-52.35

29.89

-35.42

92.99

Use logarithmic scale

	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	- -	- -	1.46	1.5	1.81	2.28	2.47	1.93	2.09	2.56	2.62	2.91
Basic EPS, GAAP	- -	- -	0.16	0.37	0.52	0.77	0.94	0.78	0.76	0.38	0.54	0.66
Free Cash Flow per Basic Share	- -	- -	0.18	0.37	0.61	0.75	0.86	0.67	-0.42	-0.43	-1.35	-1.38
Dividend per Share	- -	- -	1.47	0.02	- -	0.29	0.36	0.36	0.24	0.24	0.22	0.2
Book Value per Share	- -	- -	0.81	1.12	1.59	2	2.72	2.39	2.85	2.92	3.48	3.68
Tangible Book Value per Share	- -	- -	2.71	2.97	3.48	4	9.78	7.8	8.14	8.2	8.59	8.63
Basic Weighted Avg Shares	- -	- -	124	126	126	126	126	168	168	169	169	174
Sales/Revenue/Turnover	200	187	181	190	229	286	312	323	351	433	444	506
Operating Margin (%)	28.02	22.81	12.08	26.42	26.92	31.27	32.73	35.52	29.62	20.8	20.73	22.71
Depreciation Expense	29	30	26	27	27	28	29	26	24	27	48	- -
Net Income, GAAP	47	38	20	47	66	97	118	131	129	64	91	115
Effective Tax Rate (%)	15.78	12.83	25.54	15.37	15.07	14.03	14.31	14.45	13.66	21.19	13.63	14.22
Profit Margin (%)	23.34	20.19	10.79	24.74	28.78	33.9	37.93	40.37	36.62	14.85	20.59	22.69
Working Capital	192	241	140	192	257	319	1,057	1,071	935	727	596	564
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	2	2	1	12
Total Equity	428	466	355	403	464	526	1,250	1,324	1,382	1,425	1,494	1,541
Return on Invested Capital (%)	- -	8.14	3.64	9.81	11.35	15.47	9.94	7.72	6.69	5.03	5.42	6.46
Return on Capital (%)	- -	10.44	7.6	29.14	34.9	42.18	39.13	33.59	28.35	13.26	16.79	18.97
Return on Common Equity (%)	- -	10.4	8.14	38.75	38.51	42.9	39.71	35.07	29.18	13.2	16.84	19.07

Capital Structure

•

in mil. unless spec.

Working Capital

•

in mil. unless spec.

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)	10 years	5 years	1 year
Sales/Revenue/Turnover	8.78%	9.42%	2.39%
Net Income, GAAP	18.31%	4.56%	41.95%
Free Cash Flow	26.37%	14.94%	213.13%
Total Cash Common Dividend	17,557.08%	3.31%	-8.19%
Total Equity	18.28%	31.15%	4.83%

Growth Rates

•

in mil. unless spec.

Quarterly Revenue

•

in mil. unless spec.

Quarterly Earnings Per Share

•

in mil. unless spec.

Quarterly Dividends Per Share

•

in mil. unless spec.

Company Description

CEO: Mr. Dewei Yi
Full Time Employees: 508
Sector: Healthcare
Industry: Biotechnology
Address: No. 999 high-tech Avenue Wuhan People's Republic of China 430073
IPO Date: Dec 19, 2019
Website: cabio.cn
Similar Companies: Transgene SA (TRGNF)
PolarityTE, Inc. (PTE)
NervGen Pharma Corp. (NGENF)
Alphamab Oncology (9966.HK)
Amicogen, Inc. (092040.KQ)
3SBio Inc. (TRSBF)
Business: Cabio Biotech (Wuhan) Co., Ltd. develops, produces, and markets arachidonic and docosahexaenoic acids, and beta-carotene for domestic and foreign infant formula, and healthy food manufacturers. Its products are used in infant formula food, health food, dietary supplements, and other fields for special medical purposes, pet nutrition food, economic animal feed, personal care and cosmetics, and other fields. The company was founded in 1999 and is based in Wuhan, the People's Republic of China.

	Mar'24	Jun'24	Sep'24
Total Current Assets	695	704	672
Accounts Receivable, Net	244	246	256
Cash, Cash Equivalents & STI	232	249	159
Inventories	107	108	131
Total Current Liabilities	95	105	108
Payables & Accruals	- -	- -	- -
ST Debt	12	12	7
Deferred Revenue	- -	- -	- -

	Mar'24	Jun'24	Sep'24
ST Debt	12	12	7
LT Borrowings	- -	4	11
LT Finance Leases	1	- -	- -
Preferred Equity and Hybrid Capital	- -	- -	- -
Shares Outstanding	168	168	168
Market Capitalization	2,478	2,299	3,524

	2013 Y	2014 Y	2015 Y	2016 Y	2017 Y	2018 Y	2019 Y	2020 Y	2021 Y	2022 Y	2023 Y	TTM
Revenue per Share	- -	- -	1.46	1.5	1.81	2.28	2.47	1.93	2.09	2.56	2.62	2.91
Basic EPS, GAAP	- -	- -	0.16	0.37	0.52	0.77	0.94	0.78	0.76	0.38	0.54	0.66
Free Cash Flow per Basic Share	- -	- -	0.18	0.37	0.61	0.75	0.86	0.67	-0.42	-0.43	-1.35	-1.38
Dividend per Share	- -	- -	1.47	0.02	- -	0.29	0.36	0.36	0.24	0.24	0.22	0.2
Book Value per Share	- -	- -	0.81	1.12	1.59	2	2.72	2.39	2.85	2.92	3.48	3.68
Tangible Book Value per Share	- -	- -	2.71	2.97	3.48	4	9.78	7.8	8.14	8.2	8.59	8.63
Basic Weighted Avg Shares	- -	- -	124	126	126	126	126	168	168	169	169	174
Sales/Revenue/Turnover	200	187	181	190	229	286	312	323	351	433	444	506
Operating Margin (%)	28.02	22.81	12.08	26.42	26.92	31.27	32.73	35.52	29.62	20.8	20.73	22.71
Depreciation Expense	29	30	26	27	27	28	29	26	24	27	48	- -
Net Income, GAAP	47	38	20	47	66	97	118	131	129	64	91	115
Effective Tax Rate (%)	15.78	12.83	25.54	15.37	15.07	14.03	14.31	14.45	13.66	21.19	13.63	14.22
Profit Margin (%)	23.34	20.19	10.79	24.74	28.78	33.9	37.93	40.37	36.62	14.85	20.59	22.69
Working Capital	192	241	140	192	257	319	1,057	1,071	935	727	596	564
LT Debt	- -	- -	- -	- -	- -	- -	- -	- -	2	2	1	12
Total Equity	428	466	355	403	464	526	1,250	1,324	1,382	1,425	1,494	1,541
Return on Invested Capital (%)	- -	8.14	3.64	9.81	11.35	15.47	9.94	7.72	6.69	5.03	5.42	6.46
Return on Capital (%)	- -	10.44	7.6	29.14	34.9	42.18	39.13	33.59	28.35	13.26	16.79	18.97
Return on Common Equity (%)	- -	10.4	8.14	38.75	38.51	42.9	39.71	35.07	29.18	13.2	16.84	19.07

Year	Q1	Q2	Q3	Q4	FY
2022	76	96	102	160	433
2023	88	111	126	119	444
2024	117	144	126	- -	- -

Year	Q1	Q2	Q3	Q4	FY
2022	0.14	- -	- -	- -	0.38
2023	0.09	- -	- -	- -	0.54
2024	0.14	- -	- -	- -	- -

Cabio Biotech (Wuhan) Co., Ltd.

Growth Rates

(avg. rate of change)

Company Description

Working Capital

Capital Structure

Growth Rates

(avg. rate of change)

Quarterly Revenue

Year

Quarterly Earnings Per Share

Year

Quarterly Dividends Per Share

Year